Skip to main content

01-10-2019 | Urothelial cancer | Video

ESMO 2019: Atezolizumab shows promise in advanced urothelial cancer

Enrique Grande presents the IMvigor130 trial assessing front-line atezolizumab, either as monotherapy or alongside chemotherapy, in treatment-naïve individuals with locally advanced or metastatic urothelial carcinoma (5:54).

Funding for independent interviews at ESMO 2019 was provided in part by F.Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits